Valeant completes acquisition of Dow Pharmaceutical Sciences
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticalshas completed its $285 million acquisition of Dow Pharmaceutical Sciences. The acquisition, which was first announced early last month, will boost Valeant's US dermatology franchise with a complementary pipeline and revenue-generating contract service business. Dow is estimated to have 2008 revenues of $45 million, $20 million from royalties and $25 million from its service business (ScripOnline, December 11th, 2008).